Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast

PR Newswire March 8, 2017

Immunotherapy Companies Leading the Charge for Treating Cancer

PR Newswire February 21, 2017

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

PR Newswire February 15, 2017

TapImmune, Inc. Presentation Now Available for On-Demand Viewing

PR Newswire February 9, 2017

TapImmune Expands Intellectual Property On PolyStart™ Platform For Use In Next-Generation T-Cell Vaccines

PR Newswire February 7, 2017

TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials

PR Newswire February 2, 2017

Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd

PR Newswire January 30, 2017

TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2

PR Newswire January 30, 2017

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

PR Newswire January 24, 2017

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

PR Newswire January 10, 2017

TapImmune To Present At Biotech Showcase 2017

PR Newswire January 5, 2017

TapImmune: Year End 2016 Update

PR Newswire December 30, 2016

TapImmune To Present At The LD Micro IX Main Event, December 6-8, 2016

PR Newswire December 6, 2016

TapImmune President John Bonfiglio to Present a Corporate Update at Biotech and Money Investival Showcase

PR Newswire November 17, 2016

TapImmune Commences Trading on the Nasdaq Capital Market

PR Newswire November 8, 2016

TapImmune Approved for Listing on the Nasdaq Capital Market

PR Newswire November 3, 2016

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

PR Newswire November 1, 2016

TapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016

PR Newswire October 5, 2016

TapImmune Appoints Michael J. Loiacono as Chief Financial Officer

PR Newswire August 25, 2016

TapImmune Doses First Patient in Its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

PR Newswire June 21, 2016